학술논문
A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia
Document Type
Original Paper
Author
Miyagawa, Taku; Khor, Seik-Soon; Toyoda, Hiromi; Kanbayashi, Takashi; Imanishi, Aya; Sagawa, Yohei; Kotorii, Nozomu; Kotorii, Tatayu; Ariyoshi, Yu; Hashizume, Yuji; Ogi, Kimihiro; Hiejima, Hiroshi; Kamei, Yuichi; Hida, Akiko; Miyamoto, Masayuki; Ikegami, Azusa; Wada, Yamato; Takami, Masanori; Higashiyama, Yuichi; Miyake, Ryoko; Kondo, Hideaki; Fujimura, Yota; Tamura, Yoshiyuki; Taniyama, Yukari; Omata, Naoto; Tanaka, Yuji; Moriya, Shunpei; Furuya, Hirokazu; Kato, Mitsuhiro; Kawamura, Yoshiya; Otowa, Takeshi; Miyashita, Akinori; Kojima, Hiroto; Saji, Hiroh; Shimada, Mihoko; Yamasaki, Maria; Kobayashi, Takumi; Misawa, Rumi; Shigematsu, Yosuke; Kuwano, Ryozo; Sasaki, Tsukasa; Ishigooka, Jun; Wada, Yuji; Tsuruta, Kazuhito; Chiba, Shigeru; Tanaka, Fumiaki; Yamada, Naoto; Okawa, Masako; Kuroda, Kenji; Kume, Kazuhiko; Hirata, Koichi; Uchimura, Naohisa; Shimizu, Tetsuo; Inoue, Yuichi; Honda, Yutaka; Mishima, Kazuo; Honda, Makoto; Tokunaga, Katsushi
Source
Journal of Human Genetics. 63(12):1259-1267
Subject
Language
English
ISSN
1434-5161
1435-232X
1435-232X
Abstract
Essential hypersomnia (EHS) is a lifelong disorder characterized by excessive daytime sleepiness without cataplexy. EHS is associated with human leukocyte antigen (HLA)-DQB1*06:02, similar to narcolepsy with cataplexy (narcolepsy). Previous studies suggest that DQB1*06:02-positive and -negative EHS are different in terms of their clinical features and follow different pathological pathways. DQB1*06:02-positive EHS and narcolepsy share the same susceptibility genes. In the present study, we report a genome-wide association study with replication for DQB1*06:02-negative EHS (408 patients and 2247 healthy controls, all Japanese). One single-nucleotide polymorphism, rs10988217, which is located 15-kb upstream of carnitine O-acetyltransferase (CRAT), was significantly associated with DQB1*06:02-negative EHS (P = 7.5 × 10−9 , odds ratio = 2.63). The risk allele of the disease-associated SNP was correlated with higher expression levels of CRAT in various tissues and cell types, including brain tissue. In addition, the risk allele was associated with levels of succinylcarnitine (P = 1.4 × 10−18 ) in human blood. The leading SNP in this region was the same in associations with both DQB1*06:02-negative EHS and succinylcarnitine levels. The results suggest that DQB1*06:02-negative EHS may be associated with an underlying dysfunction in energy metabolic pathways.